The survival rate for metastatic osteosarcoma has not improved for several decades, since
the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over …

Nanomedicines suffer from poor drug loading and uncontrolled 'burst release'after
administration. Combining prodrug strategies with nanostructured carriers can help to …

Introduction Osteosarcoma is a malignant primary bone tumor. Bone marrow-derived
mesenchymal stem cells-derived extracellular vesicles (BMSC-EVs) bear repair function for …

In recent years, health authorities have encouraged the development of paediatric
formulations. New technologies have been proposed for the development of paediatric …

In recent years, the continuous development of innovative nanopharmaceuticals is
expanding their biomedical and clinical applications. Nanomedicines are being …

Pancreatic cancer (PC) is an aggressive cancer subtype presenting unmet clinical
challenges. Conventional chemotherapy, which includes antimetabolite gemcitabine (GEM) …

Osteosarcoma (OS) is the most domain primary malignant bone tumor. Treatment
resistances and metastases result in a decreasing 5‐year overall survival rate of OS …